CALL FOR PAPERS | Biomarkers in Lung Diseases: from Pathogenesis to Prediction to New Therapies

Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia

Francis Y. Kim, Elizabeth A. Barnes, Lihua Ying, Chihhsin Chen, Lori Lee, Cristina M. Alvira, and David N. Cornfield

Center for Excellence in Pulmonary Biology, Division of Pulmonary, Asthma and Sleep Medicine, Department of Pediatrics, Stanford University Medical School, Stanford, California

Submitted 4 September 2014; accepted in final form 12 November 2014


Pulmonary artery smooth muscle cells (PASMC) have the capacity to sense and respond directly to hypoxia (5, 21) and thereby modulate pulmonary vascular tone. In the context of pulmonary hypertension, hypoxia can cause vascular remodeling, which entails PASMC proliferation and migration (28). Molecules produced by PA endothelial cells (EC) modulate vascular tone by direct effects on PASMC. Nitric oxide, for example, activates guanylate cyclase and increases cytosolic cyclic GMP concentration, resulting in vasodilation (7, 11, 24).

Endothelin (ET-1), a 21-amino-acid polypeptide produced primarily by EC, possesses complex effects. ET-1 binds to specific receptors on PASMC to cause an increase in [Ca^{2+}], and vasoconstriction (40). In many pathological states, including pulmonary hypertension; smooth muscle cells

Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia.

Endothelin-1 (ET-1) increases pulmonary vascular tone through direct effects on pulmonary artery smooth muscle cells (PASMC) via membrane-bound ET-1 receptors. Circulating ET-1 contributes to vascular remodeling by promoting SMC proliferation and migration and inhibiting SMC apoptosis. Although endothelial cells (EC) are the primary source of ET-1, whether ET-1 produced by SMC modulates pulmonary vascular tone is unknown. Using transgenic mice created by crossbreeding SM22α-Cre mice with ET-1flox/flox mice to selectively delete ET-1 in SMC, we tested the hypothesis that PASMC ET-1 gene expression modulates the pulmonary vascular response to hypoxia. ET-1 gene deletion and selective activity of SM22α promoter-driven Cre recombinase were confirmed. Functional assays were performed under normoxic (21% O2) or hypoxic (5% O2) conditions using murine PASMC obtained from ET-1+/+ and ET-1−/− mice and in human PASMC (hPASMC) after silencing of ET-1 using siRNA. Under baseline conditions, there was no difference in right ventricular systolic pressure (RVSP) between SM22α-ET-1−/− and SM22α-ET-1+/+ (control) littermates. After exposure to hypoxia (10% O2, 21–24 days), RVSP was and vascular remodeling were less in SM22α-ET-1−/− mice compared with control littermates (P < 0.01). Loss of ET-1 decreased PASMC proliferation and migration and increased apoptosis under normoxic and hypoxic conditions. Exposure to selective ET-1 receptor antagonists had no effect on either the hypoxia-induced hPASMC proliferative or migratory response. SMC-specific ET-1 deletion attenuates hypoxia-induced increases in pulmonary vascular tone and structural remodeling. The observation that loss of ET-1 inhibited SMC proliferation, survival, and migration represents evidence that ET-1 derived from SMC plays a previously undescribed role in modulating the response of the pulmonary circulation to hypoxia. Thus PASMC ET-1 may modulate vascular tone independently of ET-1 produced by EC.

Thus the need to generate new knowledge that might be translated into a therapeutic tool has never been more palpable.

Pulmonary arterial hypertension (PAH) is a syndrome wherein pulmonary arterial obstruction increases PVR, resulting in right ventricular heart failure. Despite the advent of new biological-based therapies and increased insight into the pathobiology of primary pulmonary hypertension, the actuarial survival of patients has demonstrated only modest improvement, as 50% of all people with primary PAH die within 7 yr of diagnosis (1). No effective preventative or curative treatments are available. When PAH is superimposed on diseases such as bronchopulmonary dysplasia, a chronic lung disease of infancy (26), congenital heart disease, cystic fibrosis, or rheumatological disease (16), the prognosis is dramatically worsened (13). Thus the need to generate new knowledge that might be translated into a therapeutic tool has never been more palpable.

Pulmonary artery smooth muscle cells (PASMC) have the capacity to sense and respond directly to hypoxia (5, 21) and thereby modulate pulmonary vascular tone. In the context of pulmonary hypertension, hypoxia can cause vascular remodeling, which entails PASMC proliferation and migration (28). Molecules produced by PA endothelial cells (EC) modulate vascular tone by direct effects on PASMC. Nitric oxide, for example, activates guanylate cyclase and increases cytosolic cyclic GMP concentration, resulting in vasodilation (7, 11, 24).

Endothelin (ET-1), a 21-amino-acid polypeptide produced primarily by EC, possesses complex effects. ET-1 binds to specific receptors on PASMC to cause an increase in [Ca^{2+}], and vasoconstriction (40). In many pathological states, including
ing PAH (36), ET-1 production is increased, leading to an increase in vascular tone, smooth muscle cell (SMC) proliferation, migration, and survival (14, 23, 41). The importance of ET-1 in the pathobiology of PAH (31, 32) provided sound therapeutic rationale for the development of specific ET-1 receptor antagonists. Although ET-1 receptor antagonists are widely used clinically, the therapeutic efficacy has been limited (19). Given the observation that SMC can produce by SMC might function in an autocrine manner and thereby contribute to the pathology of PAH independent of ET-1 receptor activation (37, 38). Thus, to test the hypothesis that ET-1 produced by SMC is increased, leading to an increase in vascular tone, smooth muscle cell (SMC) proliferation, migration, and survival (14, 23, 41).

MATERIALS AND METHODS

**Generation of SM22α-ET-1−/− mice.** Transgenic mice with selective deletion of ET-1 (SM22α-ET-1−/− mice) in SMC were created by cross breeding SM22α-promoter-driven Cre mice expressing the Cre reporter gene ROSA26R (kindly provided by Dr. Marlene H9251/H9252-promoter-driven Cre mice expressing the Galactosidase Reporter Gene Staining Kit, Sigma-Aldrich) for 3 h at 37°C, and then fixed in 10% formalin solution for 10 min. Pulmonary artery (PA) tissues from mutant (ET-1flox/flox) and wild-type (WT) and mutant edn1-specific primers (right). B: smooth muscle cell (SMC)-specific deletion of ET-1 in SM22α-ET-1−/− mice. PA tissues from control (left) and SM22α-ET-1−/− mice (right) were stained with X-gal to detect β-gal expression. Magnification ×200. C: loss of ET-1 mRNA in pulmonary artery smooth muscle cells (PASMC) isolated from SM22α-ET-1−/− mice. D: loss of ET-1 protein in PASMC isolated from SM22α-ET-1−/− mice. PASMC (mPASMC) were incubated under hypoxic (5% O2) conditions for 24 h. Cell lysates were then assessed for ET-1 levels by ELISA. ***p < 0.001.
in DMEM containing 5% FBS, 1% L-glutamine, and 1% antibiotic-antimycotic solution (Invitrogen/Gibco). To confirm isolation of PASMC, cells were stained for α-smooth muscle actin (α-SMA) (1:400, Sigma) using immunofluorescence technique.

**Immunocytochemistry.** mPASMC isolated from control and SM22α-ET1−/− mice were fixed in 3% paraformaldehyde in PBS for 30 min, blocked and permeabilized in blocking solution (0.1% Triton X-100, 15 g/ml glycine, 2.5% FBS in PBS) for 1 h, and then incubated with ET-1 antibody (1:200, Abcam) for 1 h. Cells were then incubated with Alexa Fluor 488 Phalloidin (1:40, Invitrogen/Molecular Probes) and goat α-rabbit Alexa Fluor 568 (1:200, Invitrogen/Molecular Probes) for 30 min, followed by mounting in Vectashield Mounting Medium with DAPI (Vector Laboratories).

**Quantitative RT-PCR.** To assay for ET-1 mRNA expression, total RNA was isolated from cultured mPASMC exposed to 24-h hypoxia (5% O2) using the RNeasy Mini Kit (Qiagen). First-strand cDNA was synthesized using SuperScript III Reverse Transcriptase (Life Technologies) and subsequently amplified on the C1000 Thermal Cycler CFX 384 Real-Time System (Bio-Rad) using RT2 SYBR Green qPCR Mastermix (Qiagen). Primer sets are as follows, ET-1 forward: 5′- GTGTCTACTTCTGCCACCTGGACAT-3′ and ET-1 reverse: 5′- GGGCTCGCACTATATAAGGGATGAC-3′; GAPDH forward: 5′- GGTTCGTCCTATATAAGGGATGAC-3′; GAPDH reverse: 5′-

![Image](http://ajplung.physiology.org/)
exposed to hypoxia (5% O₂) for 24 h and then harvested and lysed. Cell lysate samples were normalized to cell number (representing group. To measure pulmonary arterial pressures, mice were anesthetized and sacrificed, and blood was collected for hemodynamic assessments. The data were analyzed using statistical software.

### Hemodynamic assessments.

Adult littermates were used in each group. To measure pulmonary arterial pressures, mice were anesthetized and sacrificed, and blood was collected for hemodynamic assessments. The data were analyzed using statistical software.

### Morphometric analysis.

Assessment of PA muscularization was performed on formalin-fixed and paraffin-embedded lung sections from mice exposed to chronic hypoxia using Movat pentachrome stain. Peripheral PA wall thickness was assessed by measuring Movat-stained vessels less than 100 μm in diameter at 10 fields/mouse at ×400 magnification using Metamorph software and then compared between the two genotypes using the following equation: medial thickness index = [(area_{ext} - area_{aqua})/area_{aqua}], where area_{ext} and area_{aqua} represent the areas within the external and internal boundaries of the elastic fibers as detected by Movat stain (8).

### Cell culture.

In vitro studies were performed with hPASMC and mPASMC isolated from control and transgenic mice with selective deletion of ET-1 in SMC (SM22α-ET-1−/−). The hPASMC were purchased from Lonza and grown according to the manufacturer’s protocol. Cells from passages 3–8 were used for all experiments.

### Apoptosis assays.

For the assays using endothelin A and B (ETA and ETB) receptor antagonists, hPASMC proliferation was determined as described above with the following exception: 7.5 μM BQ123 (ETA inhibitor) and 0.1 μM BQ788 (ETB inhibitor) were added 30 min before the addition of the BrDU-labeling reagent.

### Immunohistochemistry.

Formalin-fixed and paraffin-embedded lung sections from mice exposed to chronic hypoxia were deparaffinized and rehydrated, incubated with Universal Antigen Retrieval Reagent (R&D Systems) for 30 min at 95°C, permeabilized with 0.25% Triton X-100 in PBS solution for 30 min, incubated with 100 mM glycine solution (pH 7.5) for 20 min to quench autofluorescence, blocked with Sea Block Blocking Solution (Thermo Scientific) for 30 min, blocked with Mouse Detective Reagent (Biocare Medical) for 30 min to block endogenous mouse IgG, and incubated with proliferating cell nuclear antigen (PCNA) (1:150, Abcam) and α-SMA (1:400, Sigma) antibodies overnight at 4°C. Sections were then incubated with goat anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 568 (1:200, Invitrogen/Molecular Probes) for 1 h, followed by incubation with 1 μg/ml Hoechst solution (Sigma) to visualize nuclei. The relative number of proliferating SMC was assessed as a percentage of total SMC in PA >100 μm and <250 μm in diameter following exposure to chronic hypoxia.

### ET-1 ELISA.

Serum from control and SM22α-ET-1−/− mice 

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>SM22α-ET-1−−/−</th>
<th>Chronic Hypoxia</th>
<th>SM22α-ET-1−−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit</td>
<td>44.2 ± 0.8 (6)</td>
<td>42.0 ± 2.1 (4)</td>
<td>54.2 ± 0.6 (3)</td>
<td>56.3 ± 2.2 (3)</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>367 ± 31 (3)</td>
<td>373 ± 10.7 (4)</td>
<td>411 ± 16.7* (6)</td>
<td>419 ± 9.9* (4)</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>28.8 ± 1.3 (12)</td>
<td>30.9 ± 1.2 (10)</td>
<td>25.3 ± 2.3* (5)</td>
<td>27.3 ± 2.3* (5)</td>
</tr>
<tr>
<td>Left ventricular fractional shortening, %</td>
<td>30.0 ± 3.7 (3)</td>
<td>30.0 ± 3.9 (4)</td>
<td>34.5 ± 0.7 (5)</td>
<td>30.8 ± 1.9 (4)</td>
</tr>
<tr>
<td>Aortic valve velocity time integral, cm</td>
<td>2.45 ± 0.3 (3)</td>
<td>2.84 ± 0.5 (4)</td>
<td>2.6 ± 0.3 (5)</td>
<td>2.35 ± 0.3 (4)</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE; numbers of mice per group are in parentheses. *P < 0.05, **P < 0.001, hypoxia vs. normoxia. ET-1, endothelin-1.
inhibitor) were added 30 min before exposure to normoxia or hypoxia for 24 h.

**Cell migration assays.** SMC migration was determined by using a modified Boyden Chamber assay (BD BioCoat Matrigel Invasion Chamber, BD Biosciences). Briefly, Matrigel inserts were rehydrated with media at 37°C for 2 h before use. Media (± 10 ng/ml PDGF-BB) was added to each well of a 24-well companion plate. Transfected hPASMC (siET-1 and siNTC) and mPASMC (ET-1+/+ and ET-1−/−) were seeded (20,000 cells/well) in duplicate in the top chamber (Matrigel insert). After 24 h of incubation, the nonmigrated cells in the top chamber were carefully removed, and the migrated cells on the lower surface of the membrane were fixed and stained with Diff-Quik kit reagents (Polysciences).

For the assays using ETA and ETB receptor antagonists, hPASMC cell migration was determined as described above with the following exception: 7.5 μM BQ123 (ETA inhibitor) and 0.1 μM BQ788 (ETB inhibitor) were added to the top chamber before exposure to either normoxia or hypoxia for 24 h.

**Statistical analysis.** Results are expressed as means ± SE. Statistical significance was assessed with Student’s t-test and ANOVA where appropriate. A P value of <0.05 was taken as the threshold level for statistical significance. All experiments were repeated a minimum of three times unless stated otherwise.

**RESULTS**

**Characterization of SM22α-ET-1−/− mice.** Cre recombinase activity and edn1 gene expression in SM22α-ET-1+/+ mice was demonstrated using PCR (Fig. 1A). Lung tissues from SM22α-ET-1+/+ mice were stained with X-gal to demonstrate D

---

*Fig. 3.* Loss of SMC ET-1 inhibits the hypoxia-induced proliferative response. A: loss of ET-1 significantly decreases mPASMC proliferation under both normoxic (21% O2) and hypoxic (5% O2) conditions. Cell proliferation was measured by bromodeoxyuridine (BrdU) incorporation assay after 24 h. ***P < 0.001, ET-1+/+ vs. ET-1−/−; §§§P < 0.001, hypoxia vs. normoxia. B: representative images of proliferating cell nuclear antigen (PCNA)-expressing cells show a decrease in SMC proliferation in PA of SM22α-ET-1+/+ mice exposed to hypoxia (3 wk, 10% O2) (right). PCNA, green; Hoechst (nuclei), blue; α-smooth muscle actin, red. Magnification ×400, scale bar = 50 μm. Percentage of PASMC ≥100 μm in diameter positive for PCNA expression. Graph represents the means ± SE of the number of PCNA-positive SMC/the total number of SMC per PA; n = 3 for each genotype with a minimum of 500 cells counted per mouse. *P < 0.05, C: ET-1 knockdown with siRNA in human PASMC (hPASMC) as assessed by ELISA. ***P < 0.001, siRNA specific for human ET-1 (siET-1) vs. scrambled nontargeted control siRNA (siNTC). D: loss of ET-1 significantly decreases hPASMC proliferation under both normoxic and hypoxic conditions. hPASMC were transfected with siNTC or siET-1. Cell proliferation was measured after 24 h by BrdU incorporation assay. ***P < 0.001, siET-1 vs. siNTC; §§§P < 0.001, hypoxia vs. normoxia.
SM22α-promoter-driven Cre recombinase activity in SMC. As shown in Fig. 1B, right, β-gal expression was present in the PA of SM22α-ET-1−/− mice. In contrast, β-gal expression was undetectable in lung tissues from SM22α-ET-1+/+ mice (control, Fig. 1B, left). Both ET-1 mRNA and protein were significantly decreased in PASMC isolated from SM22α-ET-1−/− mice compared with control mice (Fig. 1, C and D). These results confirm the absence of ET-1 in SM22α-expressing cells in the present murine model. Even under hypoxic conditions, ET-1 expression is minimal.

Loss of ET-1 in SMC attenuates the pulmonary vascular response to chronic hypoxia. To characterize the role of PASMC ET-1 production on the pulmonary vascular response to hypoxia, control and SM22α-ET-1−/− mice were evaluated after hypoxic exposure. At baseline, under normoxic conditions, RVSP was 26.9 ± 1.4 mmHg in control and 25.0 ± 1.2 mmHg in SM22α-ET-1−/− mice. After 3 wk of hypoxia (10% O2), RVSP was 41.5 ± 1.2 mmHg in control mice compared with 35.8 ± 1.3 mmHg in SM22α-ET-1−/− mice (Fig. 2, A and B; P < 0.01 vs. control). Fulton’s index was determined as the ratio of right ventricular weight to LV and septal weight. (Fig. 2C). Compared with control mice, peripheral PA muscularization was significantly decreased, and the ratio of arteries to alveoli was more well preserved in SM22α-ET-1−/− mice (Fig. 2, D and E). Both groups demonstrated similar increases in hematocrit and heart rate, decreases in body weight, and well-preserved cardiac function after hypoxic exposure (Table 1). After chronic hypoxia, serum ET-1 levels increased similarly in control and SM22α-ET-1−/− mice, supporting the notion that ET-1 production from endothelial cells is the major contributor to circulating ET-1 levels as opposed to ET-1 derived from SMC (Fig. 2F).

In both experimental groups, hemoglobin increased after hypoxic exposure. LV function was preserved in both groups after hypoxia. After hypoxia, Fulton’s index did not differ between experimental groups (Fig. 2C).

ET-1 depletion inhibits the hypoxia-induced proliferation in PASMC. To gain insight into the mechanism by which SMC-derived ET-1 may mitigate the pulmonary vascular response to hypoxia, we considered whether ET-1 plays a role in SMC proliferation. Using PASMC isolated from SM22α-ET-1−/− and control mice, we compared proliferation in ET-1+/+ and ET-1−/− PASMC under normoxic and hypoxic conditions. Under normoxic conditions, loss of ET-1 decreased the rate of PASMC proliferation (Fig. 3A). Furthermore, the hypoxia-induced increase in SMC proliferation was significantly attenuated in ET-1−/− PASMC compared with ET-1+/+ PASMC. To demonstrate fidelity between in vitro and in vivo findings, we performed PCNA staining on lung tissues. After chronic hypoxia, the percentage of proliferating PASMC was decreased in SM22α-ET-1−/− compared with control mice (Fig. 3B).

To buttress the relevance of the findings from the murine model to human biology, hPASMC ET-1 was silenced in hPASMC using siRNA. As shown in Fig. 3C, ET-1 production was significantly diminished in siET-1-transfected cells (86% less than nontargeted control siRNA, siNTC). Consistent with the cell proliferation results from mPASMC, loss of ET-1 decreased proliferation of hPASMC under basal conditions and attenuated the hypoxia-induced proliferative response (Fig. 3D).

ET-1 depletion increases apoptosis in PASMC. To determine whether SMC-derived ET-1 plays a role in cell survival as well as cell proliferation, we measured the caspase 3/7 activities in ET−/− PASMC. As shown in Fig. 4A, the loss of ET-1 in mPASMC resulted in a significant increase in apoptosis compared with ET-1+/+ SMC under both normoxic and hypoxic conditions. Similarly, knockdown of ET-1 using siRNA in hPASMC resulted in a significant increase in apoptosis compared with siNTC-transfected SMC (Fig. 4B). These results demonstrate that the loss of SMC-derived ET-1 promotes PASMC apoptosis and suggest that SMC-derived ET-1 contributes to PA remodeling in response to hypoxia by promoting SMC survival.

ET-1 depletion inhibits SMC migration in PASMC. To determine the role of SMC-produced ET-1 in SMC migration, we assessed the effects of ET-1 expression on SMC migration using a modified Boyden Chamber assay. Migration was diminished in ET-1−/− mPASMC compared with ET-1+/+ cells under both normoxic and hypoxic conditions (Fig. 5A). Cell migration was similarly diminished in hPASMC transfected with siET-1 compared with siNTC cells (Fig. 5B). Interestingly, even with PDGF-BB stimulation, a promigratory stimulus for SMC (9, 15), SMC migration was attenuated in ET-1-depleted SMC compared with control cells.

Inhibition of ET-1 receptors does not alter SMC proliferation, apoptosis, or migration. To determine whether the proproliferative effect of SMC ET-1 was contingent on binding
to either the ETA or ETB receptors, cell proliferation assays were performed in the presence and absence of specific ET-1 receptor antagonists. Neither BQ123, a specific ETA receptor antagonist, nor BQ788, a specific ETB receptor antagonist (2, 12), had an effect on SMC proliferation under normoxia. Moreover, the hypoxia-induced SMC proliferative response was unaffected by either receptor antagonist (Fig. 6). To further assess the functional role of SMC ET-1, assays for apoptosis (Fig. 6B) and cell migration (Fig. 6C) were performed in the presence and absence of selective ETA or ETB receptor antagonism. Pharmacological antagonism of either receptor had no effect on either apoptosis or proliferation.

**DISCUSSION**

The present series of experiments provides evidence for a previously undescribed role for smooth muscle-derived ET-1 in the pathogenesis of PAH. Compared with controls, RVSP in SM22α-ET-1−/− mice was similar under normoxic conditions but significantly lower after chronic hypoxia. Consistent with these findings, after chronic hypoxia, vascularity was more well preserved and muscularization diminished in SM22α-ET-1−/− mice. To address the potential physiological underpinnings, we evaluated the effect of ET-1 depletion on SMC proliferation, apoptosis, and migration. Loss of ET-1 in SMC compromised both cell survival and migration, suggesting that SMC ET-1 might contribute to pulmonary vascular remodeling by augmenting proliferation and migration, while mitigating apoptosis. Finally, by demonstrating that SMC proliferation, in both hypoxia and normoxia, was not altered by ET-1 receptor blockade, we provide evidence that SMC-derived ET-1 may act independently of ET-1 receptor activation. This observation may, in part, account for the limited therapeutic benefit of ET-1 receptor blockade in the context of PAH characterized by minimal vascular reactivity and structural remodeling (22).

Although ET-1 production by SMC has been previously reported (29, 30), this is the first to demonstrate a physiologically significant role for SMC-derived ET-1 in the pathogenesis of PAH. Whether there is a physiological role for PASMC-derived ET-1 remains unknown. In the present experimental series, ET-1 derived from PASMC modulated proliferation,
apoptosis, and migration, even under normoxic conditions. Despite these functional differences, RVSP was similar between the two study groups under normoxic conditions. Differences might become evident in the context of physiological perturbations other than hypoxia, as might be the case in asthma or pneumonia. Further studies are needed to determine the functional significance of PASMC-derived ET-1 under physiological conditions.

Previous studies have demonstrated a role for ET-1 produced by EC in the regulation of peripheral vascular tone (20). Systemic blood pressure is lower in mice with EC-specific deletion of ET-1 compared to controls, suggesting a role for EC-derived ET-1 in the regulation of peripheral vascular tone (20). Further support for this construct comes from in vitro experiments. Loss of ET-1 in SMC produced similar results in murine PASMC, wherein ET-1 was never expressed, and in hPASMC, wherein ET-1 expression was silenced using RNA interference. With either approach, PASMC proliferation, migration, and apoptosis were affected, thereby establishing a proproliferative, promigratory, and prosurvival role for SMC-derived ET-1 in the pulmonary circulation. Experiments performed with pharmacological blockers of the ETA and ETB receptors suggest that the effects of ET-1 produced by SMC are not contingent on receptor activation, as antagonism did not affect, whereas ET-1 depletion blocked, the hypoxia-induced increase in proliferation. These results prompt consideration of the notion that ET-1 might play an intracellular role or signal SMC via non-ETA or -ETB receptors.
SMC consistently irrespective of cellular source, as exogenous ET-1 is proliferative (41) and promigratory (23) and prevents apoptosis (14). Hypoxia increases ET-1 production (35, 39). The present report adds to these observations by demonstrating that endogenous ET-1 modulates SMC cellular functions that are central to the pathogenesis of pulmonary hypertension. Notwithstanding these observations, how endogenous ET-1 affects SMC function and the signal transduction pathway remains unknown. Endogenous SMC ET-1 may affect migration via ERK 1/2 MAP kinases, as has been previously reported (23). Conclusions that can be drawn from the present series of experiments are limited by the discrete focus. In PASMC, there may be crosstalk between ET-1 and hypoxia-inducible factor-1α, a construct that is unaddressed in the present line of investigation (27). Furthermore, the influence, if any, of endogenous ET-1 on intracellular calcium homeostasis is similarly unaddressed.

The present findings possess important implications for ET-1 signaling in SMC. Even in the presence of pharmacological blockade of ETA and ETB receptors, hypoxia increased SMC proliferation, apoptosis, and migration. These results suggest that ET-1 may possess intracellular effect and may signal through an as yet unknown intracellular route as well as via the well-established and classical membrane-bound receptors. Evidence in support of this construct includes the observation that circulating endothelin levels may not be wholly reflective of tissue levels of endothelin (2, 10, 19, 29, 38). Hence the classical paradigm, namely that endothelin produced by endothelial cells signals predominately through membrane-bound receptors on SMC, may be meaningfully incomplete in a manner that possesses significant physiological implications. The present findings possess important clinical implications. Although ET-1 receptor blockade is relatively efficacious in less severe PAH, the therapeutic benefit is diminished in patients with more severe disease, structural remodeling, and loss of pulmonary vascular reactivity (33). Whether ET-1 produced by SMC accounts for the constrained therapeutic benefit is unknown. Conceivably, in the presence of already established SMC hypertrophy, ET-1 receptor antagonists might possess limited therapeutic effect owing to SMC-derived ET-1.

Using a murine model of SMC-specific ET-1 deletion, we demonstrate a physiologically significant role for endogenous ET-1 in the pathogenesis of PAH. ET-1 in SMC plays a role in cellular proliferation, survival, and migration, functions that are central to the vascular changes that characterize PAH. These results suggest that in PAH the therapeutic efficacy of ET-1 receptor antagonists might be limited in the presence of marked pulmonary vascular remodeling. Moreover, optimizing the therapeutic benefits of ET-1 receptor antagonists might require a strategy wherein SMC-derived ET-1 production might be limited.

ACKNOWLEDGMENTS

We thank M. Rabinovitch for the SM22α-promoter-driven Cre/ROSA26 reporter mice and M. Yanigisawa for the ET-1 flox/flox mice.

GRANTS

This work was supported by funding from the National Institutes of Health HL060784 and HL0706280 (D. Cornfield).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES


